Controlled release of phenolic opioids
View Patent ↗A method of providing a patient with controlled release of a phenolic opioid using a prodrug capable, upon enzymatic activation, of releasing the phenolic opioid through intra-molecular cyclization leading to formation of a cyclic urea, carbamate or thiocarbamate.
1. A method of treating or preventing pain comprising administering to a patient in need thereof an effective amount of a compound of structural Formula (I):
or a pharmaceutically acceptable salt thereof wherein:
X is a phenolic opioid agonist, wherein the hydrogen atom of the phenolic hydroxyl group is replaced by a covalent bond to —C(O)—Y—(C(R 1 )(R 2 )) n —N—(R 3 )(R 4 );
Y is —NR 5 — and R 5 is (1-4C)alkyl;
n is 2 or 3;
R 1 and R 2 are each hydrogen;
R 3 is hydrogen or (1-4C)alkyl; and
R 4 is a residue of an L-amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glycine, glutamine, glutamic acid, histidine, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, lysine and valine; a residue of a dipeptide composed of two L-amino acid residues or a tripeptide composed of three L-amino acid residues, wherein the amino acids are selected independently from alanine, arginine, asparagine, aspartic acid, cysteine, glycine, glutamine, glutamic acid, histidine, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, lysine and valine; or a residue of an N-acyl derivative thereof.
2. The method of claim 1 , wherein X is hydromorphone, oxymorphone, or morphine.
3. The method of claim 1 , wherein X is hydromorphone.
4. The method of claim 1 , wherein X is morphine.
5. The method of claim 1 , wherein X is oxymorphone.
6. The method of claim 1 , in which R 5 is methyl.
7. The method of claim 1 , in which R 5 is ethyl.
8. The method of claim 1 , in which R 3 is hydrogen or methyl.
9. The method of claim 1 , in which R 3 is hydrogen.
10. The method of claim 1 , in which R 4 is a residue of an L-amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glycine, glutamine, glutamic acid, histidine, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, lysine and valine.
11. The method of claim 1 , in which R 4 is a residue of an N-acyl derivative of an L-amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glycine, glutamine, glutamic acid, histidine, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, lysine and valine.
12. The method of claim 1 , in which R 4 is a residue of arginine, N-acetylarginine, N-t-butanoylarginine, N-benzoylarginine, N-piperonylarginine, N-glycinylarginine, lysine, N-acetyllysine, glutamic acid, aspartic acid, tyrosine, proline or N-glycinylproline.
13. The method of claim 12 , in which R 4 is a residue of arginine, N-acetylarginine, N-t-butanoylarginine, N-benzoylarginine, N-piperonylarginine, N-glycinylarginine, lysine, glutamic acid, proline or N-glycinylproline.
14. The method of claim 12 , in which R 4 is a residue of arginine or N-acetylarginine.
15. The method of claim 12 , in which R 4 is a residue of lysine or N-acetyllysine.
16. The method of claim 1 , wherein the compound is hydromorphone 3-(N-methyl-N-(2-N′-acetylarginylamino))ethylcarbamate, or a pharmaceutically acceptable salt thereof.
17. The method of claim 1 , wherein the compound is morphine 3-(N-methyl-N-(2-N′-acetylarginylamino))ethylcarbamate, or a pharmaceutically acceptable salt thereof.
18. The method of claim 1 , wherein the compound is oxymorphone 3-(N-methyl-N-(2-N′-acetylarginylamino))ethylcarbamate, or a pharmaceutically acceptable salt thereof.